Editorial comment

摘要

The authors evaluated the risk for fracture because of the development of osteoporosis in men with prostate cancer who were subjected to androgen deprivation therapy (ADT) in the clinical scenario of prostate-specific antigen relapse after local therapy with curative intent, such as radical prostatectomy or radiation therapy. To assess the risk of fracture, the World Health Organization Fracture Risk Calculation Tool (FRAX) was applied, and the data obtained were compared with the results of the standard bone mineral density (BMD) evaluation by dual-energy X-ray absorptiometry (DXA) scans and the objective T scores derived from DXA scans. ADT is known as a significant contributor of osteoporosis in men with prostate cancer (PCa), and once diagnosed, osteoporosis needs to be treated by bone-targeting approaches, whereas osteopenia might be managed by preventive and supportive measures.